Related Experiment Video

Updated: Oct 6, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

MicroRNAs in Pancreatic Cancer and Chemoresistance

Yue Pan1, Kun Li1, Xufeng Tao1

  • 1From the State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Sciences, School of Chemical Engineering, Dalian University of Technology, Dalian, China.

Pancreas
|January 18, 2022
PubMed

Insights

Pancreatic ductal adenocarcinoma (PDAC) drug resistance is a major challenge. Novel microRNAs are key to understanding and potentially treating this cancer by targeting resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality.
  • Development of resistance to chemotherapy and radiotherapy significantly impacts PDAC patient outcomes.
  • Multiple mechanisms contribute to drug resistance in PDAC, including altered cellular transport, metabolism, DNA damage response, and genetic mutations.

Purpose of the Study:

  • To investigate the role of microRNAs in mediating chemotherapy and radiotherapy resistance in PDAC.
  • To identify novel microRNAs that could serve as biomarkers for PDAC resistance.
  • To explore microRNAs as potential therapeutic targets for overcoming PDAC treatment resistance.

Main Methods:

  • Review of existing literature on microRNA function in cancer.
  • Analysis of molecular mechanisms underlying drug resistance in PDAC.
  • Discussion of the potential for microRNA detection in PDAC therapy.

Main Results:

  • MicroRNAs, short noncoding RNAs, regulate gene expression by binding to 3'-untranslated regions.
  • MicroRNAs can influence multiple target genes, thereby mediating resistance to chemotherapy and radiotherapy in PDAC.
  • Identification of specific microRNAs involved in PDAC resistance is crucial.

Conclusions:

  • MicroRNAs play a significant role in the development of resistance to chemotherapy and radiotherapy in pancreatic ductal adenocarcinoma.
  • Discovering novel microRNAs can elucidate PDAC's molecular mechanisms and resistance pathways.
  • MicroRNAs represent promising therapeutic targets for improving PDAC treatment strategies.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K